Biogen Inc. on Thursday said it will appeal a court ruling that
invalidated a key patent on Tecfidera, its blockbuster
multiple-sclerosis drug.
A federal court in West Virginia earlier Thursday found that generic drug maker Mylan N.V. had established that Biogen’s patent claims were invalid.
The patent was expected to last until 2028, and the ruling potentially opens the door to generic competition to Tecfidera, which accounted for roughly 30% of Biogen’s sales in the first quarter.
During Biogen’s fourth-quarter earnings conference call in January, Chief Financial Officer Jeffrey Capello said the Cambridge, Mass., company would appeal any adverse ruling in patent litigation relating to Tecfidera, and that the appeal process tends to take 12 to 18 months.
https://www.marketscreener.com/BIOGEN-INC-4853/news/Biogen-Says-Will-Appeal-Ruling-Invalidating-Tecfidera-Patent-30791823/
Edit
A federal court in West Virginia earlier Thursday found that generic drug maker Mylan N.V. had established that Biogen’s patent claims were invalid.
The patent was expected to last until 2028, and the ruling potentially opens the door to generic competition to Tecfidera, which accounted for roughly 30% of Biogen’s sales in the first quarter.
During Biogen’s fourth-quarter earnings conference call in January, Chief Financial Officer Jeffrey Capello said the Cambridge, Mass., company would appeal any adverse ruling in patent litigation relating to Tecfidera, and that the appeal process tends to take 12 to 18 months.
https://www.marketscreener.com/BIOGEN-INC-4853/news/Biogen-Says-Will-Appeal-Ruling-Invalidating-Tecfidera-Patent-30791823/
Edit
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.